> the clinical safety data is not available for third party review That’s best practice, due to the problem that access to data from past trials can bias the p

> the clinical safety data is not available for third party review That’s best practice, due to the problem that access to data from past trials can bias the planning and design of new trials. It’s SOP from hard win practical experience over many decades.